Proteomics profiling reveals a distinct high-risk molecular subtype of hypertrophic cardiomyopathy.

ABSTRACT:

Objective

Hypertrophic cardiomyopathy (HCM) is a heterogeneous disease, likely encompassing several subtypes of disease with distinct biological mechanisms (ie, molecular subtypes). Current models based solely on clinical data have yielded limited accuracy in predicting the risk of major adverse cardiovascular events (MACE). Our aim in this study was to derive molecular subtypes in our multicentre prospective cohort of patients with HCM using proteomics profiling and to examine their longitudinal associations with MACE.

Methods

We applied unsupervised machine learning methods to plasma proteomics profiling data of 1681 proteins from 258 patients with HCM who were prospectively followed for a median of 2.8 years. The primary outcome was MACE, defined as a composite of arrhyth

SUBMITTER: Liang LW 

PROVIDER: S-EPMC9741498 | biostudies-literature | 2022 Oct

REPOSITORIES: biostudies-literature